logo

For the Inventor, By the Inventor

Munich, Germany

Alexander Haas

This inventor holds 12 USPTO granted patents and 5 published patent applications. Top assignee: Hoffmann-La Roche Inc.. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alexander Haas. Retrieved from https://idiyas.com/inventor/alexander-haas-7349m4ce

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 

% Patents Active = 75.0

Average Co-Inventor Count = 5.9

ph-index = 5

Forward Citations = 42(Granted Patents)


Location History:

  • Weilheim, DE (2022)
  • Munich, DE (2014 - 2024)

Company Filing History:

goldMedal12 out of 5,026 
 
Hoffmann-La Roche Inc.
 patents

Years Active: 2014-2025

Loading Chart...
12 patents (USPTO):Explore Patents
1. 12378315 - Anti-rabbit CD19 antibodies and methods of use (2025-08-05),
2. 12227594 - Bispecific 2+1 contorsbodies (2025-02-18),
3. 12215152 - Humanized anti-human CD19 antibodies and methods of use (2025-02-04),
4. 12023378 - Covalently linked antigen-antibody conjugates (2024-07-02),
5. 11286300 - Humanized anti-human CD19 antibodies and methods of use (2022-03-29),
6. 10517945 - Covalently linked antigen-antibody conjugates (2019-12-31),
7. 9879095 - Bispecific antibodies comprising a disulfide stabilized-Fv fragment (2018-01-30),
8. 9574016 - Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent (2017-02-21),
9. 9303076 - Cell-penetrating peptides and uses thereof (2016-04-05),
10. 9303075 - Cell-penetrating peptides and uses thereof (2016-04-05),
11. 9050375 - Bi-specific digoxigenin binding antibodies (2015-06-09),
12. 8907069 - Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent (2014-12-09),

Title: Discovering the Innovations of Alexander Haas

Introduction

Alexander Haas, an esteemed inventor based in Munich, Germany, has made significant contributions to the field of biotechnology with a remarkable portfolio of 11 patents. His notable work primarily focuses on the development of novel antibodies, which hold great potential for therapeutic applications.

Latest Patents

Haas's latest patents include groundbreaking inventions such as bispecific 2+1 contorsbodies. This invention relates to novel bispecific antibodies that consist of two fusion polypeptides incorporating two antigen-binding domains capable of specific binding to a first target, along with one antigen-binding domain specific to a second target. Additionally, he has developed humanized anti-human CD19 antibodies, which are designed to bind specifically to human CD19. This antibody comprises multiple highly variable regions (HVR) with specific amino acid sequences, providing innovative solutions for targeting this critical antigen in human therapeutics.

Career Highlights

Alexander Haas is currently employed at Hoffmann-La Roche Inc., where he collaborates on various research initiatives aimed at advancing drug development. His extensive background in biotechnology research has equipped him with the skills necessary to drive forward the frontiers of therapeutic innovation.

Collaborations

Haas works alongside talented colleagues such as Guy Georges and Ulrich Brinkmann. This dynamic collaboration fosters an environment of creative synergy, enhancing the potential for developing groundbreaking solutions within their field.

Conclusion

In conclusion, Alexander Haas stands out as a prominent inventor in the biotechnology landscape, with his innovative patents playing a crucial role in the advancement of targeted therapies. His work at Hoffmann-La Roche Inc., coupled with fruitful collaborations, continues to drive forward the progress of scientific discovery and innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…